Samantha Gunning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samantha Gunning has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Rita L. McGill
Section of Nephrology, University of Chicago, Chicago, Illinois
2 shared publications - Arlene B. Chapman
Division of Nephrology, University of Chicago School of Medicine, Chicago, Illinois
1 shared publication - Louis G. Baeseman
Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL USA
1 shared publication - Olivia C. Wright
University of Chicago Chicago, IL
1 shared publication - Pranav S. Garimella
Division of Nephrology and Hypertension, University of California San Diego, San Diego, California
1 shared publication
Latest Publications
- 29 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Serum Uromodulin in Dialysis Patients
Was not provided for this article.
- 29 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Serum Uromodulin in Dialysis Patients
Was not provided for this article.
- 31 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1762-1771
Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease
Key Points: Peritoneal dialysis can be used successfully in patients with autosomal dominant polycystic kidney disease. Compared with days receiving hemodialysis, peritoneal dialysis days were associated with better patient survival, which has increased over time. Compared with hemodialysis days, peritoneal dialysis days were associated with a higher rate of kidney transplant, which has increased over time. Background: Peritoneal dialysis (PD) is a form of home dialysis that is underutilized in the United States. Patients with autosomal dominant polycystic kidney disease (ADPKD) are frequently good PD candidates who are often young and have few comorbid conditions. However, clinicians may be hesitant to recommend PD to patients with ADPKD because of perceived concerns for mechanical complications and technique failure. Little is known about outcomes of patients with ADPKD undergoing PD in the United States. Methods: A retrospective cohort of patients with ESKD 30 years and older registered in the United States Renal Data System with a diagnosis of cystic kidney disease from January 1, 2000, to December 31, 2021, was followed until death or January 1, 2023, whichever occurred first. A time-dependent variable for kidney treatment modality was created, allowing calculation of hazard ratios (HRs) and confidence intervals (CIs) on the basis of time proximity of PD exposure to death and kidney transplantation, compared with hemodialysis. Cox models were adjusted for age, sex, race, body mass index, serum albumin, hemoglobin, year of incident ESKD, insurance status, and comorbid conditions at the time of inclusion. Results: Among 53,651 incident ADPKD patients with ESKD, 26% received some PD. Over a median follow-up of 75 months, 26,375 (49%) of the patients received kidney transplants and 23,427 (44%) died. PD exposure was more likely among patients with ADPKD who were younger, were female, and had lower burden of comorbid diseases. In the adjusted models, PD was associated with lower mortality (HR, 0.84; 95% CI, 0.80 to 0.88, P < 0.001) and higher likelihood of transplant (HR, 1.12; 95% CI, 1.08 to 1.16; P < 0.001) compared with hemodialysis. The associations with lower mortality and higher transplantation became progressively more prominent with each passing year. Conclusions: These data indicate that PD is a safe and advantageous dialysis option for patients with ADPKD that is associated with longer patient survival and opportunities for kidney transplant.
- 31 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1762-1771
Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease
Key Points: Peritoneal dialysis can be used successfully in patients with autosomal dominant polycystic kidney disease. Compared with days receiving hemodialysis, peritoneal dialysis days were associated with better patient survival, which has increased over time. Compared with hemodialysis days, peritoneal dialysis days were associated with a higher rate of kidney transplant, which has increased over time. Background: Peritoneal dialysis (PD) is a form of home dialysis that is underutilized in the United States. Patients with autosomal dominant polycystic kidney disease (ADPKD) are frequently good PD candidates who are often young and have few comorbid conditions. However, clinicians may be hesitant to recommend PD to patients with ADPKD because of perceived concerns for mechanical complications and technique failure. Little is known about outcomes of patients with ADPKD undergoing PD in the United States. Methods: A retrospective cohort of patients with ESKD 30 years and older registered in the United States Renal Data System with a diagnosis of cystic kidney disease from January 1, 2000, to December 31, 2021, was followed until death or January 1, 2023, whichever occurred first. A time-dependent variable for kidney treatment modality was created, allowing calculation of hazard ratios (HRs) and confidence intervals (CIs) on the basis of time proximity of PD exposure to death and kidney transplantation, compared with hemodialysis. Cox models were adjusted for age, sex, race, body mass index, serum albumin, hemoglobin, year of incident ESKD, insurance status, and comorbid conditions at the time of inclusion. Results: Among 53,651 incident ADPKD patients with ESKD, 26% received some PD. Over a median follow-up of 75 months, 26,375 (49%) of the patients received kidney transplants and 23,427 (44%) died. PD exposure was more likely among patients with ADPKD who were younger, were female, and had lower burden of comorbid diseases. In the adjusted models, PD was associated with lower mortality (HR, 0.84; 95% CI, 0.80 to 0.88, P < 0.001) and higher likelihood of transplant (HR, 1.12; 95% CI, 1.08 to 1.16; P < 0.001) compared with hemodialysis. The associations with lower mortality and higher transplantation became progressively more prominent with each passing year. Conclusions: These data indicate that PD is a safe and advantageous dialysis option for patients with ADPKD that is associated with longer patient survival and opportunities for kidney transplant.